Haim N, Kedar A, Robinson E
Cancer Chemother Pharmacol. 1984;13(3):223-5. doi: 10.1007/BF00269034.
Among 106 patients treated with conventional-dose methotrexate (MTX) following prior therapy with cis-diamminedichloride platinum (CDDP), six died with clinical manifestations of MTX toxicity. Death occurred 6-13 days after the administration of 20-50 mg/m2 MTX. Toxicity included severe stomatitis and myelosuppression, which appeared in all six patients, skin rash in five, and diarrhea in four. Renal failure appeared in five cases and hepatic toxicity in four. All these patients had received MTX earlier without developing any serious toxicity. At the time of the last MTX administration, all had normal blood counts and also normal kidney and liver function tests. Prior therapy with CDDP may be responsible for this relatively high incidence of MTX-related deaths.
在106例先前接受过顺二氯二氨铂(CDDP)治疗后接受常规剂量甲氨蝶呤(MTX)治疗的患者中,有6例死于MTX毒性的临床表现。死亡发生在给予20 - 50 mg/m² MTX后的6 - 13天。毒性包括严重口腔炎和骨髓抑制,这在所有6例患者中均出现,5例出现皮疹,4例出现腹泻。5例出现肾衰竭,4例出现肝毒性。所有这些患者早期接受MTX治疗时均未出现任何严重毒性。在最后一次给予MTX时,所有患者的血细胞计数均正常,肝肾功能检查也正常。先前的CDDP治疗可能是导致MTX相关死亡发生率相对较高的原因。